Guantao Law Firm navigates pharmaceutical, medical device and healthcare clients on complex M&A, IP, IPO, research and development issues. Executive partner Yang Wang handles private equity, investment funds and IPOs, while Hongjiang Li directs the IP department, equipped to handle technology contract disputes, patent infringement and due diligence matters.
Legal 500 Editorial commentary
Key clients
- GENERAL Technology Venture CAPITAL Co., Ltd
- Chemclin Diagnostics Co., Ltd.
- Kemei Boyang Diagnostic Technology (Shanghai) Co., Ltd.
- Shanghai Shantai Health Technology Co., Ltd.
- RongCan (Shanghai) BioTech Co., Ltd.
- Zhengye Biotechnology Holding Limited
- Tianjin HAIHE RIVER RIVER Industry Fund Management Co., LTD
- Shandong CDH Baifu Equity Investment Partnership (Limited Partnership)
- Tianjin CDH Zhaoyuan Equity Investment Partnership
Work highlights
Assisting a state-controlled listed company in the acquisition of a controlling stake in a pharmaceutical enterprise.
Assisting on a project transferring the shares of investors in breach of capital contribution obligations in the General Technology Life Health Industry Equity Fund (Yiwu) Partnership Enterprise (Limited Partnership).
Assisting a pharmaceutical industry-listed company that intends to acquire a controlling stake in a CRO (Contract Research Organisation) industry company.
Practice head
Shuangqiang Huang
Other key lawyers
Yang Wang; Hongjiang Li